MV-003 Dysbiosis

Indicaton

Dysbiosis

ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations.

Therapeutic indications

Type of product

Other biologics

Table

Phase

Discovery
Partnering status

Not partnered
Available in

World-Wide

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

Zevtera / Mabelio (ceftobiprole)

Hospital- and community-acquired pneumonia

Marketed

Zevtera / Mabelio (ceftobiprole)

Acute bacterial skin and skin structure infections (ABSSSI)

Phase III completed